Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1005

1.

Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.

Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

J Nucl Med. 2009 Oct;50(10):1700-8. doi: 10.2967/jnumed.109.065961.

2.

Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.

Huber R, Seidl C, Schmid E, Seidenschwang S, Becker KF, Schuhmacher C, Apostolidis C, Nikula T, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3922S-8S.

3.

Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.

Yao Z, Zhang M, Garmestani K, Axworthy DB, Mallett RW, Fritzberg AR, Theodore LJ, Plascjak PS, Eckelman WC, Waldmann TA, Pastan I, Paik CH, Brechbiel MW, Carrasquillo JA.

Clin Cancer Res. 2004 May 1;10(9):3137-46.

4.

Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Fazel J, Rötzer S, Seidl C, Feuerecker B, Autenrieth M, Weirich G, Bruchertseifer F, Morgenstern A, Senekowitsch-Schmidtke R.

Cancer Biol Ther. 2015;16(10):1526-34. doi: 10.1080/15384047.2015.1071735. Epub 2015 Jul 15.

PMID:
26177233
5.

213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.

Beck R, Seidl C, Pfost B, Morgenstern A, Bruchertseifer F, Baum H, Schwaiger M, Senekowitsch-Schmidtke R.

Cancer Sci. 2007 Aug;98(8):1215-22. Epub 2007 Jun 11.

6.

Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.

Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL, et al.

Cancer Res. 1994 Aug 15;54(16):4362-70.

7.

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s.

8.

Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.

Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):841-9. Epub 2007 Jan 6.

PMID:
17206415
9.

Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.

Tosi E, Valota O, Negri DR, Adobati E, Mazzoni A, Meazza R, Ferrini S, Colnaghi MI, Canevari S.

Int J Cancer. 1995 Sep 4;62(5):643-50.

PMID:
7665239
10.

Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F.

J Nucl Med. 2010 Apr;51(4):624-31. doi: 10.2967/jnumed.109.070714.

11.

Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis.

van der Horst G, van Asten JJ, Figdor A, van den Hoogen C, Cheung H, Bevers RF, Pelger RC, van der Pluijm G.

Eur Urol. 2011 Aug;60(2):337-43. doi: 10.1016/j.eururo.2011.05.005. Epub 2011 May 19.

PMID:
21616583
12.

Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.

van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA.

Int J Cancer. 1998 Jul 3;77(1):13-8.

13.

Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.

Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So AI.

Clin Cancer Res. 2008 Mar 1;14(5):1510-8. doi: 10.1158/1078-0432.CCR-07-4475.

14.

²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.

Pickhard A, Piontek G, Seidl C, Kopping S, Blechert B, Mißlbeck M, Brockhoff G, Bruchertseifer F, Morgenstern A, Essler M.

Nucl Med Biol. 2014 Jan;41(1):68-76. doi: 10.1016/j.nucmedbio.2013.09.010. Epub 2013 Oct 9.

PMID:
24210808
15.

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.

J Nucl Med. 2005 Nov;46(11):1907-15.

16.

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.

Cancer Res. 2001 Jul 15;61(14):5355-61.

17.

Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.

Song EY, Qu CF, Rizvi SM, Raja C, Beretov J, Morgenstern A, Apostolidis C, Bruchertseifer F, Perkins A, Allen BJ.

Cancer Biol Ther. 2008 Jan;7(1):76-80. Epub 2007 Oct 8.

PMID:
18347423
18.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.

19.

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK.

Cancer Res. 2001 Jul 15;61(14):5349-54. Erratum in: Cancer Res 2001 Oct 15;61(20):7703-5.

20.

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.

J Nucl Med. 2006 Jul;47(7):1127-35.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk